Anxiolytic herbal supplement
Kava Kava
Kava's kavalactones reached peak plasma levels 1 to 3 hours after an oral dose in a study of ten healthy volunteers; none of the sources cited gives a half-life, and the app lists about 9 hours.1
Kava Kava after one dose: 50% at ~9 h, 25% at 18 h, 12.5% at 27 h.
Drawn from the half-life in the app's model, ~9 h. The model's figures
- Compound
- Kava Kava
- Symbol
- KAV
- Family
- Supplements
- Parts
- 13
- References
- 13
- Checked
- Last reviewed . Sources are listed below.
Overview
Kava kava (Piper methysticum) is a shrub of the pepper family that is native to the South Pacific.2 In the United States, the National Center for Complementary and Integrative Health (NCCIH) states that kava products are sold as dietary supplements, and in some other countries as drugs or herbal medicines.2 The plant's characteristic constituents are the kavalactones, and the sum of the six major kavalactones has been used to standardize kava products.3
The app files kava kava as a supplement in the anxiolytic herb group, with an oral route and a moderate evidence grade. The app's notes describe non-noble (tudei) cultivars as carrying hepatotoxicity risk that has largely been resolved with proper sourcing; Bian and colleagues write that whether and to what extent differing trial outcomes are due to different kava compositions "remains an open question".3 Bian and colleagues (Nutrients, 2020) report that in Vanuatu kava cultivars fall into four groups, and that "only the cultivars classified as noble kava are permitted for export".3 The same review states that "There are a number of factors that may contribute to such a risk, which can be reduced if not eliminated", and judges kava's "hepatotoxic risk is very low".3 NCCIH, updated April 2025, states that "Various kava products have been linked to rare cases of liver injury, some of which have been serious or even fatal", and that it "has been suggested" that undesirable cultivars or inappropriate plant parts may be responsible.2 A 16-week trial in 171 people used an extract that Bian and colleagues describe as made "with a noble kava cultivar", and it still recorded more frequent liver enzyme elevations on kava than on placebo (see Deeper analysis: the 16-week generalised anxiety disorder trial).3,10
How it works
The app's notes describe kava as a GABA-A allosteric modulator. Most of the mechanism findings cited here come from laboratory preparations, and Bian and colleagues note that biochemical and in vitro assays have used concentrations much higher than those reported in blood, work that "may not be physiologically relevant"; the only human data cited on this topic are gene-variant analyses within anxiety trials.3 Bian and colleagues summarise three studies of kava components and the GABA pathway; one observed "only weak activity on GABAA binding sites in rat brain synaptosomal membranes with weak effects on benzodiazepine binding".3 In a second study, "kavain (300 μM) positively modulated human recombinant GABAA receptors expressed in Xenopus", with "no enhancement of GABAARs via the classical benzodiazepine binding site".3 In a third study, "a kava extract enhanced the binding of the potent GABAAR agonist muscimol, with maximal potentiation in the hippocampus".3 In the 16-week generalised anxiety disorder trial, variants of the GABA transporter gene SLC6A1 were tested as moderators of response, and "No SLC6A1 polymorphisms were associated with treatment response".10 In the 6-week trial, within the kava group, GABA transporter polymorphisms rs2601126 (P = 0.021) and rs2697153 (P = 0.046) were associated with HAMA reduction.8 The app's notes describe kava as having no dependence profile. The registry entry for the University of Florida pharmacokinetic trial states that "its clinical use shows no signs of addiction or withdrawal", a description by the study team, and Bian and colleagues write that "kava consumption appears to be clinically non-addictive".4,3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~9 h
- Bioavailability
- 50%
- Typical dose
- 70–250 mg/dose kavalactones
- Route
- Oral
- Time to peak
- ~1.5 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the cited sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~9 h | Not reported in the only human pharmacokinetic study identified, which sampled blood to 12 hours and estimated parameters by non-compartmental analysis; none of the sources cited gives a kavalactone half-life1 |
| Bioavailability | 50% | No absolute bioavailability figure is given in the cited sources; the pharmacokinetic study gave oral doses only1 |
| Time to peak | ~1.5 h | 1 to 3 hours for five kavalactones after a single oral dose; mean Tmax 1.3 to 1.9 hours in the single-dose group and 1.2 to 1.8 hours in the three-times-a-day group1 |
| Effect of food | Not an app figure | Absorption of kavalactones was significantly reduced when a capsule was taken with food, in the multiple-dose arm1 |
Deeper analysis: the kavalactone pharmacokinetic study
Kanumuri and colleagues (University of Florida), Journal of Ethnopharmacology, 2022, report what they call "the first clinical pharmacokinetic study" of kavalactones after an oral dose of a standardized extract.1 Ten healthy volunteers (5 men and 5 women, median age 21 years, range 18–40) were randomised into two groups of five.1 One group received 225 mg of kavalactones as a single dose (three 75 mg capsules) and the other received one 75 mg capsule three times in the day; the capsules were free of flavokavains A and B.1 After the single dose, the peak concentration of dihydrokavain was 173.5 ± 173.1 ng/mL against 112.0 ± 117.2 ng/mL for kavain, although kavain made up about 44% of the capsule content.1 The authors write that "A dose proportionality in pharmacokinetics was established from 75 to 225 mg of kavalactone doses".1 They report that "higher exposure to the kavalactones was observed after single-dosing (225 mg), while a longer duration of exposure was observed after three times a day (3 x 75 mg) dosing".1 Safety findings were limited to this small group: "No major clinically relevant adverse events were observed in any of the volunteers, and no liver function abnormalities were noted in any volunteer over the 12 weeks of follow-up".1 The registry results for the same study list no deaths and no serious events among the 10 volunteers, and one other event, "Itching two days post dose", in the three-times-a-day group.4 Stated limitations: "Data fitting approaches using different compartmental models were unsuccessful", and "Substantial inter-subject variability was observed, and we were unable to identify the source of this variability with the covariates available".1 The authors add that "Additional studies with larger sample sizes will thus be required to better understand the population pharmacokinetics of major kavalactones".1 Funding was an NCCIH grant (R61AT009988) and the University of Florida Clinical and Translational Science Institute, and the authors declare no competing financial interests.1 The registry entry for the study (NCT03843502) names the University of Florida as lead sponsor, NCCIH as a collaborator and Thorne HealthTech, Inc. as an industry-class collaborator, and describes the study as collecting "pharmacokinetic data of kava in healthy subjects".4
Human studies
The table lists randomised, placebo-controlled trials, two pooled analyses (the Cochrane review and Connor 2006) of kava in anxiety, plus the pharmacokinetic study; it is a selection, not a complete list of the literature.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Pittler and Ernst, Cochrane Database of Systematic Reviews, 20035 | Systematic review of randomised, double-blind, placebo-controlled trials; meta-analysis of trials reporting the Hamilton Anxiety total score5 | 12 trials, n=700; 7 trials, n=380 in the meta-analysis5 | Kava extract versus placebo; the authors write of short-term treatment of 1 to 24 weeks5 | Weighted mean difference 3.9 (95% CI 0.1 to 7.7; p = 0.05); the sensitivity analysis of DSM-diagnosed non-psychotic anxiety gave 1.0, not significant (p = 0.4, n = 282); the authors call the effect small and lacking robustness5 |
| Sarris and colleagues, Psychopharmacology, 2009 (KADSS)6 | Randomised, double-blind, placebo-controlled crossover6 | 60 adults with 1 month or more of elevated generalised anxiety6 | Aqueous kava extract, 250 mg kavalactones/day (five tablets); 3 weeks6 | Hamilton Anxiety Scale change -9.9 against -0.8 with placebo in the first phase and -10.3 against +3.3 in the second; effect size d = 2.24; no serious adverse effects and no clinical hepatotoxicity6 |
| Sarris and colleagues, Human Psychopharmacology, 20127 | Randomised, double-blind crossover of kava, oxazepam and placebo, one week apart7 | 22 moderately anxious adults aged 18 to 657 | One acute dose each: kava 180 mg kavalactones, oxazepam 30 mg, placebo7 | Anxiety fell with oxazepam (p = 0.035), did not change with kava and rose in the placebo condition; kava had no negative effect on cognition, whereas alertness fell with oxazepam (p < 0.001)7 |
| Sarris and colleagues, Journal of Clinical Psychopharmacology, 20138 | Double-blind, randomised, placebo-controlled, with a 1-week placebo run-in8 | 75 adults with generalised anxiety disorder enrolled; 58 in the intention-to-treat analysis8 | Aqueous kava extract, 120 or 240 mg kavalactones/day depending on response; 6 weeks8 | Anxiety reduction favoured kava (P = 0.046, Cohen d = 0.62); remission 26% against 6% (P = 0.04); more headaches on kava (P = 0.05)8 |
| Connor and colleagues, International Clinical Psychopharmacology, 20069 | Pooled analysis of three randomised, double-blind, placebo-controlled trials, one with a venlafaxine comparator9 | Adult outpatients with DSM-IV generalised anxiety disorder; pooled n=64 (kava 28, placebo 30, venlafaxine 6)9 | Dose and length not given in the PubMed record | No significant differences between treatment groups in any trial; no effects for kava in the pooled analysis, and a significant effect favouring placebo in participants with higher baseline anxiety9 |
| Sarris and colleagues, Australian and New Zealand Journal of Psychiatry, 202010 | Phase III, multi-site, two-arm, randomised, double-blind, placebo-controlled10 | 171 non-medicated adults with diagnosed generalised anxiety disorder10 | Aqueous extract of dried kava root, 120 mg kavalactones twice a day; 16 weeks10 | Anxiety reduction not significantly different (relative reduction favouring placebo of 1.37 points; p = 0.25); remission 17.4% on kava and 23.8% on placebo (p = 0.46); more liver function test abnormalities on kava10 |
| Kanumuri and colleagues, Journal of Ethnopharmacology, 20221 | Randomised two-group pharmacokinetic study, no placebo group1 | 10 healthy volunteers aged 18 to 401 | 225 mg kavalactones as one dose, or 75 mg three times in a day; blood sampled to 12 hours, liver tests followed for 12 weeks1 | Tmax 1 to 3 hours; exposure was higher after the single dose and lasted longer with three doses; no liver function abnormalities in follow-up1 |
The NCCIH page, updated April 2025, says that "Kava supplements may be helpful for anxiety, but they may need to be taken for several weeks to produce an effect", and that "Kava does not appear to be helpful for symptoms of generalized anxiety disorder".2
Deeper analysis: the 16-week generalised anxiety disorder trial
Sarris and colleagues (NICM Health Research Institute, Western Sydney University, and the University of Melbourne), Australian and New Zealand Journal of Psychiatry, 2020, ran a phase III trial in Australia.10 The authors set out to perform "a larger, longer-term trial" of kava in generalised anxiety disorder and to test whether GABA transporter polymorphisms moderated response.10 The extract was aqueous, from dried kava root, "standardised to 120 mg of kavalactones twice/day", in 171 non-medicated adults with diagnosed generalised anxiety disorder.10 The primary result was null: "a non-significant difference in anxiety reduction between the Kava and placebo groups (a relative reduction favouring placebo of 1.37 points; p = 0.25)".10 Remission was 17.4% on kava and 23.8% on placebo (p = 0.46).10 On genetics, "carriers of the rs2601126 T allele preferentially respond to placebo (p = 0.006)".10 On adverse events the authors write: "Kava was well tolerated aside from poorer memory (Kava = 36 vs placebo = 23; p = 0.044) and tremor/shakiness (Kava = 36 vs placebo = 23; p = 0.024) occurring more frequently in the Kava group".10 On the liver they report that abnormalities in liver function tests "were significantly more frequent in the Kava group, although no participant met criteria for herb-induced hepatic injury".10 Bian and colleagues, in a review, add that the elevations appeared "as early as 2 weeks", that the kava group "were also reported to have a higher incidence of alcohol use", and that the extract contained flavokavains A and B (4.35%), which they call "different from the other reports about aqueous kava preparations".3 The authors conclude that "this particular extract was not effective for diagnosed generalised anxiety disorder".10 Bian and colleagues note that "the three trials by Sarris used three different kava preparations" and that whether the differing outcomes owe to composition "remains an open question".3 The PubMed record gives the publication type "Research Support, Non-U.S. Gov't" and carries no funding statement, competing-interest statement or discussion of limitations, so these are not reproduced here.10 Bian and colleagues state that the extract used in this trial was "prepared by Integria Healthcare, specifically for this trial".3 The registry entry (NCT02219880) lists the University of Melbourne as lead sponsor, with Swinburne University of Technology and the University of Queensland as collaborators, all of class OTHER, and gives the status as completed.11 Its design text differs from the paper: it describes "an 18-week double-blind, randomised, placebo-controlled study" of 240 mg kavalactones a day in a planned 210 adults, against 16 weeks and 171 analysed participants in the paper.11
Deeper analysis: the 6-week generalised anxiety disorder trial
Sarris and colleagues (Department of Psychiatry, University of Melbourne), Journal of Clinical Psychopharmacology, 2013, enrolled "75 participants with GAD and no comorbid mood disorder" in a 6-week double-blind trial of an aqueous kava extract against placebo.8 The intention-to-treat analysis covered 58 participants who met inclusion criteria after a 1-week placebo run-in, so 17 of those enrolled were not in the primary analysis.8 The primary outcome was the Hamilton Anxiety Rating Scale, and the result was "a significant reduction in anxiety for the kava group compared with the placebo group with a moderate effect size (P = 0.046, Cohen d = 0.62)".8 Among participants with moderate to severe diagnosed GAD, "this effect was larger (P = 0.02; d = 0.82)", and remission was 26% on kava against 6% on placebo (P = 0.04).8 For safety the authors write: "Kava was well tolerated, and aside from more headaches reported in the kava group (P = 0.05), no other significant differences between groups occurred for any other adverse effects, nor for liver function tests".8 The authors conclude that "Standardized kava may be a moderately effective short-term option for the treatment of GAD".8 The PubMed record gives the publication type "Research Support, Non-U.S. Gov't" and carries no funding statement, competing-interest statement or discussion of limitations.8 Bian and colleagues state that the kava tablets used in this trial "were prepared by Integria Healthcare".3
Deeper analysis: the Cochrane review of kava extract
Pittler and Ernst (Department of Complementary Medicine, University of Exeter), Cochrane Database of Systematic Reviews, 2003, searched EMBASE, MEDLINE and other databases, with searches "updated to August 2002".5 The full text counts 12 trials (n=700); the PubMed summary of the same record counts eleven trials and 645 participants, with a difference of 5.0 (95% CI 1.1 to 8.8; p = 0.01; n = 345).5 In the meta-analysis of seven trials the difference was 3.9 (95% CI 0.1 to 7.7; p = 0.05; n = 380), with heterogeneity ("chi square = 27.5; p = 0.0001") attributed mainly to two outlying trials.5 A sensitivity analysis limited to non-psychotic anxiety diagnosed by DSM criteria gave a difference of 1.0 with a non-significant effect (p = 0.4; n = 282).5 The authors state that "The effect lacks robustness and is based on a relatively small sample".5 After removing the two outlying trials, the remaining five trials gave a difference of 3.4 (95% CI 0.5 to 6.4; p = 0.02; n = 305), and the authors' conclusion reads "Compared with placebo, kava extract is an effective symptomatic treatment for anxiety although, at present, the size of the effect seems to be small".5 On adverse events they report that "Stomach complaints, restlessness, drowsiness, tremor, headache and tiredness were reported most frequently", that "None of the trials reported any hepatotoxic events", and that seven trials measured liver enzymes and "report no clinically signifcant changes".5 Their stated limitations include that "it is conceivable that some were not uncovered" and that "Therefore the possibility of treatment effects to be exaggerated exists".5 Funding was internal (Peninsula Medical School, Universities of Exeter and Plymouth), with "No sources of support supplied" from outside, and the conflict of interest statement reads "None".5
Doses reported in studies and on labels
The app's typical dose is 70–250 mg per dose of kavalactones. No kava product label or regulator dosing document was among the sources cited, so every figure below comes from a study or review.
| Setting | Dose reported | Length and people | Reference |
|---|---|---|---|
| Pharmacokinetic study, healthy volunteers | 225 mg kavalactones as one dose, or 75 mg three times in a day | One day of dosing, blood to 12 hours, n=10 | Kanumuri 20221 |
| Acute dose against oxazepam and placebo | 180 mg kavalactones, single dose | One dose per condition, 1 week apart, n=22 | Sarris 20127 |
| Generalised anxiety, 3-week crossover | 250 mg kavalactones/day | 3 weeks, n=60 | Sarris 20096 |
| Generalised anxiety, 6 weeks | 120 or 240 mg kavalactones/day depending on response | 6 weeks, 75 enrolled, 58 analysed | Sarris 20138 |
| Generalised anxiety, 16 weeks | 120 mg kavalactones twice a day | 16 weeks, n=171 | Sarris 202010 |
| Post-marketing surveillance studies cited in the Cochrane review | Kava extract equivalent to 105 mg to 240 mg kavalactones per day | 5 to 7 weeks, 7078 patients in two drug monitoring studies | Pittler and Ernst 20035 |
| Dietary supplements on the US market, as described in a review | Daily dose of 60–250 mg kavalactones | One or two months | Bian 20203 |
| Traditional Pacific use, as estimated in the review | 750 to 8000 mg kavalactones/day | Varies by region | Bian 20203 |
The review gives supplement doses per day, while the app's figure is per dose.3
Side effects reported
NCCIH states that "Kava can cause digestive upset, headache, dizziness, and other side effects".2 It adds that "Long-term use of high doses of kava may cause kava dermopathy", described as dry, scaly, flaky skin.2 NCCIH advises against using kava together with other sedative substances such as benzodiazepines or alcohol.2 It also states that kava "may have special risks if taken during pregnancy or while breastfeeding because of the presence of harmful pyrone constituents".2 The 6-week trial reported more headaches on kava (P = 0.05), and the 16-week trial reported poorer memory and tremor or shakiness more often on kava.8,10 The Cochrane authors describe the adverse events in the trials they reviewed as "mild, transient and infrequent".5 In the single-dose crossover with oxazepam, kava had no negative effect on cognition, whereas a reduction in alertness occurred in the oxazepam condition.7
Bloodwork and markers
The app lists liver enzymes (ALT, AST) as the marker to monitor. Teschke's clinical review (Annals of Hepatology, 2010) analysed 14 patients with suspected kava liver disease and rated causality as "highly probable (n = 1), probable (n = 4) or possible (n = 9)".12 The review states that "Based on one positive reexposure test with the kava drug, it was indeed confirmed that kava is potentially hepatotoxic".12 It lists "overdose, prolonged treatment, and comedication" as risk factors in most of the 14 patients, and concludes that hepatotoxicity "occurred independently of the used solvent".12 The PubMed record of this single-author review gives no funding statement.12 Bian and colleagues describe one case after traditional kava drunk in Samoa, with "AST, 1,602 U/L; ALT, 2,841 U/L; ALP, 285 U/L".3 From the US Food and Drug Administration adverse event reporting system, the same review counts "a total of 30 adverse event reports between 2004 and 2019" potentially associated with kava, and puts them at "no more than 0.045 cases per million kava daily doses", while saying "these data are not rigorous".3 In trials, the 6-week trial reported no differences in liver function tests, the 16-week trial reported more frequent abnormalities on kava, and the pharmacokinetic study reported none over 12 weeks of follow-up in 10 volunteers.8,10,1 Bian and colleagues write that "There has only been a limited number of kava clinical trials in the past 15 years due its hepatotoxic risk."3
Regulatory and anti-doping status
NCCIH states that "Unlike drugs, dietary supplements are not approved by the U.S. Food and Drug Administration (FDA) before they are sold to the public".2 Teschke reports that "A regulatory ban for ethanolic and acetonic kava extracts was issued in 2002 for Germany", and Bian and colleagues state that "Although the ban was lifted in 2014" more clinical data are required before kava re-enters as a clinical anxiolytic.12,3 Kava is not named in the text of the World Anti-Doping Agency Prohibited List 2026, which came into effect on 1 January 2026.13
What is not known
None of the sources cited gives a kavalactone half-life or an absolute oral bioavailability, so the app's figures of about 9 hours and 50% lack a source figure beside them.1 The only human pharmacokinetic study identified enrolled 10 people and reports that "Substantial inter-subject variability was observed".1 Trial results for anxiety differ: a significant benefit in a 6-week trial, a null result in a 16-week trial, and a pooled analysis of three trials (n=64) with no effect for kava and an effect favouring placebo in participants with higher baseline anxiety.8,10,9 Whether the liver risk differs by cultivar, plant part, solvent or co-exposure remains discussed rather than settled: Bian and colleagues ask "is kava bad or are there bad types of kava?".3 The Cochrane review states that long-term safety studies of kava are needed, and the 2013 and 2020 trials cited here ran 6 and 16 weeks.5,8,10
Frequently asked questions
What is the half-life of kava?
How long does kava take to reach peak levels?
Kavalactones reached their maximum plasma concentration 1 to 3 hours after a single oral dose in a study of ten healthy volunteers, and the app lists about 1.5 hours.1
What are kavalactones?
Is kava banned by WADA?
Kava is not named in the text of the WADA Prohibited List 2026.13
Is kava approved by the FDA?
NCCIH states that kava products are sold in the United States as dietary supplements, which are not approved by the FDA before they are sold.2
Can kava affect the liver?
NCCIH states that "Various kava products have been linked to rare cases of liver injury, some of which have been serious or even fatal".2 In a 16-week trial of 171 people, liver function test abnormalities were significantly more frequent on kava than on placebo, and no participant met criteria for herb-induced hepatic injury.10
Did kava beat placebo for anxiety in trials?
Results differ between trials: a 16-week trial of 171 people found no significant difference (p = 0.25), while a 6-week trial of 58 analysed participants favoured kava (P = 0.046).10,8 A Cochrane meta-analysis of seven trials (n=380) gave a weighted mean difference of 3.9 (95% CI 0.1 to 7.7), and its authors call the effect small and lacking robustness.5
Does food change how kava is absorbed?
In the three-times-a-day arm of a ten-volunteer study (5 volunteers), the second capsule was given after food and the authors report that absorption of kavalactones "was reduced significantly with food intake", with a second Cmax about half the first, while the AUC0-4h after the first and second doses was comparable.1
Guides, tools and comparisons
References
- Kanumuri SRR, et al. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers. J Ethnopharmacol 2022. PMC9634089
- National Center for Complementary and Integrative Health. Kava: Usefulness and Safety. Last updated April 2025. NCCIH kava page
- Bian T, et al. Kava as a Clinical Nutrient: Promises and Challenges. Nutrients 2020. PMC7600512
- University of Florida. A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics. ClinicalTrials.gov NCT03843502. NCT03843502
- Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003. Cochrane review
- Sarris J, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 2009. PMID 19430766
- Sarris J, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates. Hum Psychopharmacol 2012. PMID 22311378
- Sarris J, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2013. PMID 23635869
- Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006. PMID 16877894
- Sarris J, et al. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry 2020. PMID 31813230
- University of Melbourne. Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial. ClinicalTrials.gov NCT02219880. NCT02219880
- Teschke R. Kava hepatotoxicity: a clinical review. Ann Hepatol 2010. PMID 20720265
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list